Characteristics of 31 patients in the study
. | Data . |
|---|---|
| Median age, y (range) | 51 (25-59.6) |
| No. male/no. female | 17/14 |
| Histology, no. (%) | |
| Follicular grade 1 | 1 (3) |
| Follicular grade 2 | 7 (23) |
| Follicular grade 3 | 4 (13) |
| Diffuse large B-cell | 14 (45) |
| Mantle cell | 5 (16) |
| B symptoms at diagnosis, no. (%) | 12 (38) |
| Stage at diagnosis, no. (%) | |
| I-II | 6 (19) |
| III-IV | 25 (81) |
| Extranodal involvement at diagnosis, no. (%) | 19 (61) |
| Bone marrow involvement at diagnosis, no. (%) | 17 (55) |
| Prior chemo regimens, median no. (range) | 2 (1-6) |
| Prior rituximab, no. (%) | 29* (94) |
| Disease status at ASCT, no. (%) | |
| First CR/PR | 7 (23) |
| Second or greater CR | 10 (32) |
| Relapse | 9 (29) |
| Induction failure | 5 (16) |
. | Data . |
|---|---|
| Median age, y (range) | 51 (25-59.6) |
| No. male/no. female | 17/14 |
| Histology, no. (%) | |
| Follicular grade 1 | 1 (3) |
| Follicular grade 2 | 7 (23) |
| Follicular grade 3 | 4 (13) |
| Diffuse large B-cell | 14 (45) |
| Mantle cell | 5 (16) |
| B symptoms at diagnosis, no. (%) | 12 (38) |
| Stage at diagnosis, no. (%) | |
| I-II | 6 (19) |
| III-IV | 25 (81) |
| Extranodal involvement at diagnosis, no. (%) | 19 (61) |
| Bone marrow involvement at diagnosis, no. (%) | 17 (55) |
| Prior chemo regimens, median no. (range) | 2 (1-6) |
| Prior rituximab, no. (%) | 29* (94) |
| Disease status at ASCT, no. (%) | |
| First CR/PR | 7 (23) |
| Second or greater CR | 10 (32) |
| Relapse | 9 (29) |
| Induction failure | 5 (16) |
Eight alone, 21 with chemotherapy.